Founded in Delaware, Okogen, Inc. is a biotechnology company with a core mission to innovate and enhance ophthalmic anti-infective treatments. The company's vision centers on improving lives through better vision care. Okogen's primary product, currently in clinical trials, aims to serve as a comprehensive treatment for all forms of acute infectious conjunctivitis, including both bacterial and viral types. This positions Okogen to address a significant need in the ophthalmic pharmaceutical market.

Notable figures affiliated with Okogen include experienced professionals in biotechnology and ophthalmology, although specific names are not provided. The company has achieved key milestones by advancing its lead product through clinical trials, demonstrating its potential efficacy as a "one stop shop" treatment for pink eye. Okogen's impact lies in its innovative approach to treating a common and highly contagious eye condition, potentially improving patient outcomes and reducing the spread of infection.